Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $24.61 Consensus PT from Analysts

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a […]

Leave a Reply

Your email address will not be published.

Previous post Quisitive Technology Solutions, Inc. (CVE:QUIS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Next post Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from Brokerages